IRD
Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.27
+8.65%Nov 2, 2026, 21:39 UTC
Opus Genetics approved equity awards under its 2021 Inducement Plan for 10 new non-executive employees as an inducement to employment.
Source:Oct 21, 2026, 11:00 UTC
The U.S. Food and Drug Administration cleared Opus Genetics, Inc.’ IND application for OPGx-RDH12, enabling clinical development for RDH12-associated Leber congenital amaurosis.
Source:Oct 16, 2026, 16:00 UTC
The U.S. Food and Drug Administration approved Opus Genetics, Inc.’ supplemental New Drug Application for phentolamine ophthalmic solution 0.75% to treat presbyopia in adults.
Source:Sep 9, 2026, 14:48 UTC
Opus Genetics reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, showing vision improvements.
Source:Aug 6, 2026, 00:00 UTC
Opus Genetics, Inc. reported its Q2 2026 financial results, with revenue of $0.8 million, a net loss of $8.1 million, and diluted EPS of -$0.14, compared to a net loss of $7.4 million in Q2 2025.
Source: